Featured Research

from universities, journals, and other organizations

New Drug Protects Against Second Heart Attack Or Stroke, Study Suggests

Date:
September 5, 2008
Source:
Duke University Medical Center
Summary:
Data from a Phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy, according to researchers.

Data from a Phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy, according to researchers at the Duke Clinical Research Institute.

Related Articles


While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, the scientists said.

Apixaban, one of several new anti-platelet agents under development, targets the activity of Factor Xa, an enzyme involved in the process of blood coagulation. Physicians say the need for safer, better anticoagulants is critical because current therapies fall short of therapeutic goals or are difficult to manage because they increase the risk of bleeding.

"One of the most vexing problems in cardiology is identifying the right combination of drugs that can inhibit clot formation but not increase the risk of serious bleeding," said study lead John Alexander, M.D., a cardiologist at Duke University Medical Center, who presented the findings September 2 at the European Society of Cardiology meeting in Munich.

Millions of patients worldwide take anti-clotting drugs on a regular basis. Most are prescribed aspirin, clopidogrel (also known as Plavix or Iscover) and/or warfarin.

"Warfarin is clearly effective as an anticoagulant, but it is especially hard to manage properly and safely," Alexander said. "What's driving research in this area is the fact that although aspirin and clopidogrel both offer heart attack patients important protection against blood clots, there is still room for improvement. Studies show that a significant number of patients taking aspirin and clopidogrel will still experience some sort of problem related to a blood clot. Adding warfarin just increases the likelihood of bleeding complications at a higher rate than anybody is comfortable with."

Alexander, along with Professor Lars Wallentin from the Uppsala Clinical Research Center in Sweden and other colleagues, studied the use of apixaban in 1,715 patients from 14 countries throughout Europe and North America who had suffered a recent heart attack. Roughly two-thirds of the patients had undergone angioplasty to clear blocked arteries and 99 percent of them were taking either aspirin or aspirin and clopidogrel.

The study (called APPRAISE) was designed to identify the optimal dose of apixaban. Participants were randomized into one of four doses of apixaban or a placebo. Researchers tracked the incidence of bleeding and recurrent heart attack, stroke, chest pain requiring hospitalization or additional procedures or death from cardiovascular problems for the following six months.

At the end of the study, researchers discovered a non-statistically significant trend suggesting that patients taking apixaban along with their regular treatment had a lower incidence of heart attack, stroke, chest pain or death from cardiovascular problems than patients taking a placebo.

But bleeding was an issue, especially among those taking the higher doses of the drug (10 milligrams twice daily or 20 milligrams once daily). Investigators discontinued those two arms of the study because patients were experiencing unacceptable rates of bleeding. Patients in the remaining arms of the study (2.5 milligrams twice daily or 10 milligrams once daily) also experienced more bleeding than those taking a placebo.

Investigators say that while the results are not conclusive, they do warrant further study.

"The data show adding 5 or 10 milligrams of apixaban to a regimen of aspirin or aspirin and clopidogrel in patients hoping to prevent a second heart attack may offer therapeutic potential," says Alexander. "But this needs to be definitively demonstrated in a statistically significant manner in large, well-controlled studies."

Apixaban is under development at Bristol-Myers Squibb, the company that sponsored the study.

Alexander and Wallentin have both received research support from Bristol-Myers Squibb.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "New Drug Protects Against Second Heart Attack Or Stroke, Study Suggests." ScienceDaily. ScienceDaily, 5 September 2008. <www.sciencedaily.com/releases/2008/09/080902074559.htm>.
Duke University Medical Center. (2008, September 5). New Drug Protects Against Second Heart Attack Or Stroke, Study Suggests. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2008/09/080902074559.htm
Duke University Medical Center. "New Drug Protects Against Second Heart Attack Or Stroke, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/09/080902074559.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins